Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in rhesus monkeys

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 76-86

  Martinez Navio, José M ^a   Fuchs, Sebastian P ^a,b   Pedreño López, Sònia ^a   Rakasz, Eva G ^c   Gao, Guangping ^d   Desrosiers, Ronald C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF WISCONSIN   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; PARVOVIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CORRELATION ANALYSIS; GERM LINE; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LIGHT CHAIN; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION AND DOSAGE; ANIMAL; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; HIV INFECTIONS; IMMUNOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIBODIES, VIRAL; DEPENDOVIRUS; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL VACCINES;

EID: 84957851323     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.191     Document Type: Article

References (42)

1. Burton, DR and Mascola, JR (2015). Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16: 571-576
2. Klein, F, Mouquet, H, Dosenovic, P, Scheid, JF, Scharf, L and Nussenzweig, MC (2013). Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199-1204
3. Kwong, PD, Mascola, JR and Nabel, GJ (2013). Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13: 693-701
4. Kwong, PD and Mascola, JR (2012). Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37: 412-425
5. Walker, LM, Huber, M, Doores, KJ, Falkowska, E, Pejchal, R, Julien, JP et al.; Protocol G Principal Investigators. (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470
6. Burton, DR, Desrosiers, RC, Doms, RW, Koff, WC, Kwong, PD, Moore, JP., et al. (2004). HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236
7. Hastie, E and Samulski, RJ (2015). Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success-a personal perspective. Hum Gene Ther 26: 257-265
8. Daya, S and Berns, KI (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21: 583-593
9. Gonçalves, MA (2005). Adeno-associated virus: from defective virus to effective vector. Virol J 2: 43
10. McCarty, DM (2008). Self-complementary AAV vectors; advances and applications. Mol Ther 16: 1648-1656
11. Schultz, BR and Chamberlain, JS (2008). Recombinant adeno-associated virus transduction and integration. Mol Ther 16: 1189-1199
12. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355
13. Johnson, PR, Schnepp, BC, Zhang, J, Connell, MJ, Greene, SM, Yuste, E., et al. (2009). Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15: 901-906
14. Saunders, KO, Wang, L, Joyce, MG, Yang, ZY, Balazs, AB, Cheng, C., et al. (2015). Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal simian-human immunodeficiency virus infection. J Virol 89: 8334-8345
15. Fuchs, SP, Martinez-Navio, JM, Piatak, M Jr, Lifson, JD, Gao, G and Desrosiers, RC (2015). AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog 11: e1005090
16. Gardner, MR, Kattenhorn, LM, Kondur, HR, von Schaewen, M, Dorfman, T, Chiang, JJ., et al. (2015). AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519: 87-91
17. Balazs, AB, Chen, J, Hong, CM, Rao, DS, Yang, L and Baltimore, D (2012). Antibodybased protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84
18. Xu, JL and Davis, MM (2000). Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13: 37-45
19. Nishimura, Y, Shingai, M, Willey, R, Sadjadpour, R, Lee, WR, Brown, CR., et al. (2010). Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84: 4769-4781
20. Scheid, JF, Mouquet, H, Ueberheide, B, Diskin, R, Klein, F, Oliveira, TY., et al. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637
21. Scharf, L, Scheid, JF, Lee, JH, West, AP Jr, Chen, C, Gao, H., et al. (2014). Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7: 785-795
22. Mouquet, H, Scharf, L, Euler, Z, Liu, Y, Eden, C, Scheid, JF., et al. (2012). Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 109: E3268-E3277
23. Huang, J, Ofek, G, Laub, L, Louder, MK, Doria-Rose, NA, Longo, NS., et al. (2012). Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412
24. Richman, DD, Wrin, T, Little, SJ and Petropoulos, CJ (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100: 4144-4149
25. Wei, X, Decker, JM, Wang, S, Hui, H, Kappes, JC, Wu, X., et al. (2003). Antibody neutralization and escape by HIV-1. Nature 422: 307-312
26. Walker, LM, Phogat, SK, Chan-Hui, PY, Wagner, D, Phung, P, Goss, JL et al.; Protocol G Principal Investigators. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289
27. Boisgerault, F and Mingozzi, F (2015). The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer. Curr Gene Ther 15: 381-394
28. Cao, O, Hoffman, BE, Moghimi, B, Nayak, S, Cooper, M, Zhou, S., et al. (2009). Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17: 1733-1742
29. Wardemann, H, Yurasov, S, Schaefer, A, Young, JW, Meffre, E and Nussenzweig, MC (2003). Predominant autoantibody production by early human B cell precursors. Science 301: 1374-1377
30. Wang, C, Liu, Y, Cavanagh, MM, Le Saux, S, Qi, Q, Roskin, KM., et al. (2015). B-cell repertoire responses to varicella-zoster vaccination in human identical twins. Proc Natl Acad Sci USA 112: 500-505
31. Shimizu, Y, Meunier, L and Hendershot, LM (2009). pERp1 is significantly up-regulated during plasma cell differentiation and contributes to the oxidative folding of immunoglobulin. Proc Natl Acad Sci USA 106: 17013-17018
32. Feige, MJ, Hendershot, LM and Buchner, J (2010). How antibodies fold. Trends Biochem Sci 35: 189-198
33. Scinicariello, F, Engleman, CN, Jayashankar, L, McClure, HM and Attanasio, R (2004). Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 111: 66-74
34. Calvas, P, Apoil, P, Fortenfant, F, Roubinet, F, Andris, J, Capra, D., et al. (1999). Characterization of the three immunoglobulin G subclasses of macaques. Scand J Immunol 49: 595-610
35. Zhang, H, Yang, B, Mu, X, Ahmed, SS, Su, Q, He, R., et al. (2011). Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19: 1440-1448
36. Ahmed, SS, Li, H, Cao, C, Sikoglu, EM, Denninger, AR, Su, Q., et al. (2013). A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice. Mol Ther 21: 2136-2147
37. Zufferey, R, Donello, JE, Trono, D and Hope, TJ (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-2892
38. Schambach, A, Bohne, J, Baum, C, Hermann, FG, Egerer, L, von Laer, D., et al. (2006). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther 13: 641-645
39. Giudicelli, V, Brochet, X and Lefranc, MP (2011). IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc 2011: 695-715
40. Ruiz, M and Lefranc, MP (2002). IMGT gene identification and Colliers De Perles of human immunoglobulins with known 3D structures. Immunogenetics 53: 857-883
41. National Research Council, IoLAR, Commission on Life Sciences. Guide for the Care and Use of Laboratory Animals. The National Academies Press: Washington, DC, 1996
42. Pommié, C, Levadoux, S, Sabatier, R, Lefranc, G and Lefranc, MP (2004). IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J Mol Recognit 17: 17-32